You are here: Industry Insights > leukaemia

News List

AbbVie, Roche eye first-line use of Venclexta in leukaemia pharmaphorum
December 17, 2018
AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena......
Leukaemia combination therapy effective in Phase II trial europeanpharmaceuticalreview
November 14, 2018
A Phase II clinical trial using combination therapy to treat leukaemia has shown positive results, with a Phase III clinical trial initiated…
NICE issues draft guidance rejecting Abbvie's Venclyxto in chronic lymphocytic leukaemia pharmafile
October 31, 2018
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health and Care Excellence (NICE) has announced its decision not to ...
AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia pharmaceutical-technology
September 21, 2018
AstraZeneca and its research and development arm MedImmune have obtained approval from the US Food and Drug Administration (FDA) for the use of Lumoxiti to treat adults with relapsed or refractory hairy cell leukaemia.
NHS scraps restriction on availability of J&J's Imbruvica in leukaemia patients pharmafile
August 13, 2018
The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), expanding its use to cover treatment-naïve patients with chronic lymphoblastic forms of the c
NICE recommends Pfizer's Besponsa in rare leukaemia following review pharmafile
August 10, 2018
Pfizer has revealed that NICE has finally decided to recommend its CD22-targeting monoclonal antibody Besponsa (inotuzumab ozogamicin) in the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adult patient
Tasigna cleared for use in children with rare leukemia pharmatimes
July 20, 2018
The US Food and Drug Administration is allowing use of Novartis’ Tasigna to treat paediatric patients with a rare form of leukaemia.
NICE issues decision on Mylotarg, Besponsa for leukaemia pharmatimes
July 11, 2018
The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute
New approach identifies existing leukaemia drugs that show promise for Ewing sarcoma treatment europeanpharmaceuticalreview
February 01, 2018
Scientists in the United States have discovered that two existing FDA-approved drugs, clofarabine (Clolar™) and cladribine (Leustatin™), have a powerful inhibitory impact on Ewing sarcoma cells in the lab.
Study shows that flu vaccines not effective in leukaemia patients europeanpharmaceuticalreview
October 18, 2017
Leukaemia patients who were vaccinated against influenza were just as likely as their unvaccinated peers to develop flu...

Previous page 1 2 3 Next page